Anti-CD123 CAR-T with Autologous SCT and Venetoclax Maintenance for Refractory BPDCN: Case Report

Background and article scope

The referenced article, published in Frontiers in Immunology, is a case report and literature review addressing treatment of refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) using a combined approach: Anti-CD123 CAR-T therapy, autologous stem cell transplantation (autologous SCT), and maintenance therapy with venetoclax. The title further specifies that the patient was ineligible for allogeneic transplantation, which is the context for selecting an alternative consolidation and maintenance strategy.

Availability of source content and limitations

The material supplied for this editorial rewrite contained only the journal navigation and header content from the Frontiers in Immunology site; the substantive article text (abstract, case description, methods, results, discussion, figures, tables, and references) was not included in the provided source. Therefore, this rewrite must restrict itself to facts explicit in the provided source text (principally the article title and journal attribution). Any specific clinical data, outcomes, dosing, timelines, adverse events, or literature-review conclusions were not available and are not reported here.

Case report: reported scope from the title

From the article title alone, the key clinical elements reported by the authors are:

• The diagnosis: refractory BPDCN.
• A therapeutic sequence or combination involving Anti-CD123 CAR-T therapy, followed by autologous SCT, and with venetoclax used as maintenance therapy.
• The patient was considered ineligible for allogeneic transplantation, which likely informed the choice of autologous consolidation and maintenance strategy.

No additional patient-level characteristics (age, sex, comorbidities), disease history (prior therapies, duration of refractory disease), or objective response data are available in the supplied source text.

Treatment strategy indicated by the title

The title implies a multimodal strategy combining: immunotherapy with CAR-T cells directed at the CD123 antigen, hematopoietic stem cell rescue using autologous SCT, and targeted small-molecule maintenance with venetoclax. These elements suggest an intent to achieve disease control with cellular therapy, consolidate response with transplantation, and suppress residual disease with BCL-2 inhibition on a maintenance basis. However, the authors’ rationale for sequencing, eligibility criteria for each modality, conditioning regimens, CAR-T construct details, and venetoclax regimen were not reported in the provided content.

Eligibility for transplantation and rationale mentioned in the title

The title states the patient was "ineligible for allogeneic transplantation." This identifies a clinical constraint that likely influenced the therapeutic plan. Common reasons for allogeneic ineligibility (advanced age, comorbidities, lack of donor, prior infections, or performance-status limitations) are not specified in the available source. Therefore, the precise reason the treating team chose autologous SCT over allogeneic transplantation cannot be stated from the provided text.

What the source did not report (missing details)

Because the supplied source text lacked the article body, the following key items were not available and are explicitly not reported here:

• Patient demographics and baseline clinical status.
• Prior lines of therapy and criteria defining "refractory" disease in this case.
• Details of the Anti-CD123 CAR-T product (construct, manufacturing, dose, lymphodepletion regimen).
• Timing and conditioning regimen for the autologous SCT and stem cell source/collection details.
• Venetoclax dosing, schedule, duration of maintenance, and monitoring strategy.
• Response assessments (rates of complete remission, partial remission, or measurable residual disease), duration of response, and survival outcomes.
• Adverse events or complications attributable to CAR-T, SCT, or venetoclax (for example, cytokine release syndrome, neurotoxicity, graft failure, cytopenias, infections).
• Results of the literature review component and how this case compares to previously published cases or series.

Implications and recommended next steps for readers

This rewrite is constrained to the bibliographic and title-level information present in the provided source. Clinicians, researchers, and other readers seeking the full clinical and scientific detail should consult the complete article in Frontiers in Immunology for:

• Full case description and timelines.
• Detailed treatment protocols and supportive-care measures.
• Objective outcomes and safety data.
• The authors’ literature-review synthesis and interpretation.

Because substantive clinical details were not provided in the SOURCE JINA BODY used for this task, any attempt to summarize outcomes or to extrapolate treatment efficacy or safety beyond what is in the title would require access to the full published article. The present document aims to accurately reflect what is known from the supplied material and to identify specific missing elements that readers will need to review in the original source.